---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041544"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:56:06.748808+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics Q3 net loss $17.5M; cash >$50M; LCA5 gene therapy gains FDA RMAT

## Summary
- Q3 net loss of $17.5M ($0.25/sh) vs $7.5M ($0.29/sh) in prior year; revenue $3.1M from Viatris collaboration.
- Cash $30.8M at Sep 30; raised $23M post-quarter; total >$50M expected to fund into H2 2027.
- Positive LCA5 data: 3-month pediatric and 18-month adult gains in cone-mediated vision; FDA RMAT meeting supports accelerated approval pathway.
- BEST1 gene therapy trial recruiting; initial data Q1 2026. Phentolamine sNDA for presbyopia planned by year-end 2025.
- Non-dilutive funding: $1.6M from RDH12 Alliance and $2M from Retinal Degeneration Fund for MERTK program.

## SEC filing metadata
- accession: 0001140361-25-041544
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/0001140361-25-041544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/ef20058670_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041544
- JSON: https://secwatch.observer/filing/0001140361-25-041544.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.